JP2020517703A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517703A5
JP2020517703A5 JP2019558411A JP2019558411A JP2020517703A5 JP 2020517703 A5 JP2020517703 A5 JP 2020517703A5 JP 2019558411 A JP2019558411 A JP 2019558411A JP 2019558411 A JP2019558411 A JP 2019558411A JP 2020517703 A5 JP2020517703 A5 JP 2020517703A5
Authority
JP
Japan
Prior art keywords
amino acid
composition according
free amino
composition
isoleucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019558411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517703A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/029908 external-priority patent/WO2018201024A1/en
Publication of JP2020517703A publication Critical patent/JP2020517703A/ja
Publication of JP2020517703A5 publication Critical patent/JP2020517703A5/ja
Pending legal-status Critical Current

Links

JP2019558411A 2017-04-28 2018-04-27 アミノ酸組成物及び外傷性脳損傷の治療のためのそれらの使用 Pending JP2020517703A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491796P 2017-04-28 2017-04-28
US62/491,796 2017-04-28
PCT/US2018/029908 WO2018201024A1 (en) 2017-04-28 2018-04-27 Amino acid compositions and their use for the treatment of traumatic brain injury

Publications (2)

Publication Number Publication Date
JP2020517703A JP2020517703A (ja) 2020-06-18
JP2020517703A5 true JP2020517703A5 (cg-RX-API-DMAC7.html) 2021-06-17

Family

ID=62165694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019558411A Pending JP2020517703A (ja) 2017-04-28 2018-04-27 アミノ酸組成物及び外傷性脳損傷の治療のためのそれらの使用

Country Status (5)

Country Link
US (1) US11617731B2 (cg-RX-API-DMAC7.html)
EP (1) EP3615018A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020517703A (cg-RX-API-DMAC7.html)
CN (1) CN110678172A (cg-RX-API-DMAC7.html)
WO (1) WO2018201024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
BR112020025831A2 (pt) 2018-06-20 2021-03-23 Axcella Health Inc. métodos de fabricação de composições de aminoácidos
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT201900002109A1 (it) * 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000454A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
US20220218640A1 (en) * 2021-01-14 2022-07-14 Rob Dickerman Amino acid delivery system
US11737999B2 (en) 2021-07-26 2023-08-29 Axcella Health Inc. Amino acid compositions and methods for the treatment of post-acute sequelae of COVID-19
CN119235838A (zh) * 2024-11-04 2025-01-03 苏州市立医院 一种hmb在制备改善创伤性脑损伤药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438144A (en) 1980-07-31 1984-03-20 Blackburn George L Amino acid preparation and therapy for treatment of stress and injury
WO1997025883A1 (de) * 1996-01-17 1997-07-24 Friedrich Kisters Aminosäuren-präparat zur haarwuchsförderung
EP1372641A4 (en) * 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
JP2004123564A (ja) * 2002-09-30 2004-04-22 Inst Of Physical & Chemical Res 中枢機能改善用アミノ酸組成物
US20050107338A1 (en) 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
JP4815752B2 (ja) * 2004-04-01 2011-11-16 味の素株式会社 アミノ酸含有飲食品
WO2006102451A2 (en) 2005-03-21 2006-09-28 Abbott Laboratories Amino acid composition for improving glucose tolerance
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
GB0624879D0 (en) 2006-12-14 2007-01-24 Shs Int Ltd Treatment of pervasive development disorders
JP2009106217A (ja) * 2007-10-31 2009-05-21 Ajinomoto Co Inc 増粘剤とアミノ酸を含有する食品組成物
EP2351562A4 (en) * 2008-10-27 2012-09-05 Ajinomoto Kk SOLID SOLUTION OF VALIN, ISOLEUCIN AND LEUCIN AND MANUFACTURING PROCESS THEREFOR
WO2012047800A1 (en) * 2010-10-06 2012-04-12 Abbott Laboratories Methods for increasing muscle glucose uptake and decreasing muscle recovery time using amino acid blend
WO2012106654A1 (en) 2011-02-04 2012-08-09 Hough Ear Institute Methods for treating brain injury
US20130090356A1 (en) 2011-06-24 2013-04-11 Jon D. Kaiser Compositions and methods for treatment of neuropsychological deficits
EP2580967A1 (en) 2011-10-11 2013-04-17 Nestec S.A. Accelerating muscle recovery after immobilization-induced muscle atrophy
US9101580B2 (en) 2012-12-18 2015-08-11 Matthew Bennett Compositions and methods for treating traumatic brain injury
US20160058726A1 (en) * 2013-04-16 2016-03-03 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of brain injury
US20180125926A1 (en) 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
SG11201602012RA (en) 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
US20180133185A1 (en) 2016-11-11 2018-05-17 The Children's Hospital Of Philadelphia Compositions and Methods for the Improvement of Memory
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JOP20190147A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
US20190046486A1 (en) 2017-08-14 2019-02-14 Axcella Health Inc. Compositions and methods for the treatment of neuronal injury
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
BR112020025831A2 (pt) 2018-06-20 2021-03-23 Axcella Health Inc. métodos de fabricação de composições de aminoácidos
US11298332B2 (en) 2018-06-20 2022-04-12 Axcella Health Inc. Compositions for therapy and health containing amino acids with bitter taste
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
WO2019246221A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders

Similar Documents

Publication Publication Date Title
JP2017532343A5 (cg-RX-API-DMAC7.html)
SA519402405B1 (ar) مركبات مثبط فيروس نقص المناعة البشري
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2016509011A5 (cg-RX-API-DMAC7.html)
JP2019533722A5 (cg-RX-API-DMAC7.html)
EP2444082A3 (en) Hydroxymethylbutyrate compositions and uses thereof
RU2015149387A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
JP2020521797A5 (cg-RX-API-DMAC7.html)
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
ZA202201828B (en) Therapeutic fusion proteins
WO2018053029A8 (en) Methods for treating pulmonary disease using inter-alpha inhibitor proteins
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
JP2018531929A5 (cg-RX-API-DMAC7.html)
JP2018529666A5 (cg-RX-API-DMAC7.html)
ZA201901370B (en) Formulations for oral administration of active agents
BR112021017203A2 (pt) Leucina, acetil leucina e análogos relacionados para o tratamento de doenças
JP2017519763A5 (cg-RX-API-DMAC7.html)
EA201792237A1 (ru) Фармацевтические составы
EP4663184A3 (en) Compositions for reducing the incidence of bpd
UA122336C2 (uk) Бісамідна похідна дикарбонової кислоти як засіб, що стимулює регенерацію тканин і відновлення знижених функцій тканин
RU2015134356A (ru) Пептид
JP2019519466A5 (cg-RX-API-DMAC7.html)
PH12020500001A1 (en) Non-pulsatile prolonged-release betahistine oral solid compositions
JP2018043942A5 (cg-RX-API-DMAC7.html)